Natus Medical is set to broaden its neurological portfolio, with the Can$62.5m ($64m) purchase of Excel-Tech, an Oakville, Ontario-based company specialising in developing computer-based diagnostic systems for neurological and sleep disorders. San Carlos, California-based Natus definitively agreed to purchase all outstanding Excel-Tech shares at Can$3.25 per share. Natus said that the deal will confirm its presence as a market leader in neurology and represent a stepping stone to its goal of growing revenue to $250m by the end of 2008. The company believes that the acquisition, expected to close in the first week of December, will be immediately accretive to earnings - Excel-Tech reported revenue of Can$32.5m for the 12 months ending July 31 2007. Excel-Tech will be able to offer its range of EEG patient monitoring systems for epilepsy diagnosis, electromyography systems and intra-operative monitoring systems, to over 80 countries via Natus' distribution routes.
Excel-Tech buy to add to Natus neurology offering
Natus Medical is set to broaden its neurological portfolio, with the Can$62.5m ($64m) purchase of Excel-Tech, an Oakville, Ontario-based company specialising in developing computer-based diagnostic systems for neurological and sleep disorders. San Carlos, California-based Natus definitively agreed to purchase all outstanding Excel-Tech shares at Can$3.25 per share. Natus said that the deal will confirm its presence as a market leader in neurology and represent a stepping stone to its goal of growing revenue to $250m by the end of 2008. The company believes that the acquisition, expected to close in the first week of December, will be immediately accretive to earnings - Excel-Tech reported revenue of Can$32.5m for the 12 months ending July 31 2007. Excel-Tech will be able to offer its range of EEG patient monitoring systems for epilepsy diagnosis, electromyography systems and intra-operative monitoring systems, to over 80 countries via Natus' distribution routes.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
By addressing disparities in health literacy, particularly in the areas of oral care, bone health, nutrition and air pollution, the consumer health industry can “save lives and billions in healthcare costs, boosting productivity and increasing GDP,” says a new report from Haleon and Economist Impact.
Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.
During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.